Jaguar Health, Inc. (JAGX) · Nov 3, 2026 · Other events
No new info — 5 common shares per Series R share; 13,345,986 shares outstanding
Jaguar Health’s 8-K confirms the scheduled Series R preferred-stock conversion, expanding the common share count without changing the company’s operating plan.
Jaguar Health is a development-stage biotech focused on moving crofelemer into rare intestinal-failure indications, with a targeted mid-2027 FDA application for microvillus inclusion disease while it evaluates strategic alternatives.
This filing completes a previously announced capital-structure step. Each outstanding Series R preferred share automatically converted into five common shares on November 2, 2026. 〔0〕
| Metric | November 2, 2026 | Comparison |
|---|---|---|
| Series R conversion ratio (Conversion) | 5 common shares | — |
| Common shares outstanding (Conversion) | 13,345,986 | — |
| Potential shares tied to Eligible Warrants (Conversion) | 69,823 | — |
The share count is the main consequence, not a new financing. Jaguar reported 13,345,986 common shares outstanding immediately after the conversion, while eligible warrant holders retain rights to up to 69,823 additional shares. 〔1〕 〔2〕 This changes the capitalization table and makes the potential dilution visible in common-share terms, but it does not provide cash, alter the crofelemer program, or resolve the strategic review.
The market had already been told this was coming. The October 2 announcement disclosed the one-for-one preferred dividend and the five-for-one conversion date, so the November 3 8-K is confirmation of a scheduled corporate action rather than a fresh strategic development.
Bottom line: The conversion is complete, but it barely changes Jaguar’s underlying business story. It is a routine cap-table update while investors still await progress on the strategic alternatives and rare-disease development plans.
Special stockholder meeting, November 6, 2026
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!